Cancer of unknown primary site

Researchers are testing a vaccine called BNT113 in people whose cancers are driven by HPV16, a common virus linked to head and neck, cervical, and anogenital tumors. The trial enrolls two groups: one with head and neck cancer that has been treated and shows no signs of disease, a…

This phase 2 trial is investigating whether the immunotherapy drug pembrolizumab (Keytruda) can help people with a rare and aggressive cancer called carcinoma of unknown primary (CUP), where doctors cannot find where the cancer started. Participants have not received prior treatm…

This phase 3 trial tested whether a yeast-derived immune stimulant (GM-CSF) and a peptide vaccine, alone or together, could prevent melanoma from returning after surgery. 815 patients with no visible cancer after complete surgical removal of advanced melanoma were randomly assign…

This study tested the immunotherapy drug pembrolizumab in 35 adults with cancer of unknown primary (CUP), a cancer that starts in an unknown location. Participants received the drug intravenously, and researchers measured how many saw their tumors shrink or disappear. The goal wa…

This study tested whether adding denosumab (a bone-strengthening drug) to standard immunotherapy (pembrolizumab or nivolumab) could help control advanced melanoma that has spread. Researchers enrolled 25 adults with stage III or IV melanoma who had not received prior immunotherap…

This early study tested combining the immunotherapy drug pembrolizumab with precise radiation (stereotactic radiosurgery) in 25 people with melanoma or lung cancer that had spread to the brain. The main goal was to check for serious side effects. Researchers also tracked how long…

This phase 2 trial tested the drug sintilimab in 10 people with advanced cancer of unknown primary (CUP), a rare cancer where doctors cannot find where it started. Participants received sintilimab every 3 weeks for up to 24 months. The study measured how many patients' tumors shr…

This study tested whether using a person's tumor genetic profile to choose treatment works better than standard chemotherapy for cancer of unknown primary (CUP). About 529 adults whose cancer was controlled after initial chemo were randomly assigned to either gene-guided therapy …

This completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…